Tenax Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Tenax Therapeutics de winst en omzet met respectievelijk 35.1% en 74.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 45.1% per jaar.

Belangrijke informatie

35.1%

Groei van de winst

45.1%

Groei van de winst per aandeel

Biotechs winstgroei	27.0%
Inkomstengroei	74.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	24 Oct 2024

Recente toekomstige groei-updates

Recent updates

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Sep 15

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Jan 20

Winst- en omzetgroeiprognoses

NasdaqCM:TENX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-33	N/A	N/A	5
12/31/2025	N/A	-28	N/A	N/A	5
12/31/2024	N/A	-16	N/A	N/A	5
6/30/2024	N/A	-13	-11	-11	N/A
3/31/2024	N/A	-10	-9	-9	N/A
12/31/2023	N/A	-8	-6	-6	N/A
9/30/2023	N/A	-7	-7	-7	N/A
6/30/2023	N/A	-8	-8	-8	N/A
3/31/2023	N/A	-10	-10	-10	N/A
12/31/2022	N/A	-11	-11	-11	N/A
9/30/2022	N/A	-12	-12	-12	N/A
6/30/2022	N/A	-13	-12	-12	N/A
3/31/2022	N/A	-11	-11	-11	N/A
12/31/2021	N/A	-32	-11	-11	N/A
9/30/2021	N/A	-32	-10	-10	N/A
6/30/2021	N/A	-31	-9	-9	N/A
3/31/2021	N/A	-31	-10	-10	N/A
12/31/2020	N/A	-10	-9	-9	N/A
9/30/2020	N/A	-10	-9	-9	N/A
6/30/2020	N/A	-10	-8	-8	N/A
3/31/2020	N/A	-9	-8	-8	N/A
12/31/2019	N/A	-8	-8	-8	N/A
9/30/2019	N/A	-15	-7	-7	N/A
6/30/2019	N/A	-14	-7	-7	N/A
3/31/2019	N/A	-15	-6	-6	N/A
12/31/2018	N/A	-14	-6	-5	N/A
9/30/2018	N/A	-6	-6	-6	N/A
6/30/2018	N/A	-6	-5	-5	N/A
3/31/2018	N/A	-7	N/A	-10	N/A
12/31/2017	N/A	-9	N/A	-12	N/A
9/30/2017	N/A	-37	N/A	-14	N/A
6/30/2017	N/A	-40	N/A	-17	N/A
3/31/2017	N/A	-42	N/A	-17	N/A
12/31/2016	N/A	-44	N/A	-16	N/A
9/30/2016	0	-19	N/A	-18	N/A
6/30/2016	0	-17	N/A	-17	N/A
3/31/2016	N/A	-18	N/A	-14	N/A
12/31/2015	N/A	-15	N/A	-13	N/A
10/31/2015	0	-14	N/A	-11	N/A
7/31/2015	0	-15	N/A	-12	N/A
4/30/2015	0	-14	N/A	-10	N/A
1/31/2015	0	-20	N/A	-11	N/A
10/31/2014	0	-21	N/A	-11	N/A
7/31/2014	0	-23	N/A	-10	N/A
4/30/2014	0	-25	N/A	-9	N/A
1/31/2014	1	-18	N/A	-8	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat TENX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat TENX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat TENX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat TENX volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat TENX volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van TENX naar verwachting over 3 jaar hoog zal zijn

Tenax Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast to breakeven in 2026

Price target increased by 16% to US$110

Forecast to breakeven in 2023

Price target decreased to US$4.00

Forecast to breakeven in 2022

Price target increased to US$4.75

Recent updates

New minor risk - Profitability

Tenax Therapeutics, Inc. announced that it has received $99.681169 million in funding from a group of investors

Tenax Therapeutics, Inc. announced that it expects to receive $99.681169 million in funding from a group of investors

New minor risk - Share price stability

Tenax Therapeutics, Inc. announced that it expects to receive $99.999996 million in funding from a group of investors

New major risk - Revenue and earnings growth

Tenax Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Profitability

Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients

Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer

Tenax Therapeutics Receives Non-Compliance Notice from Nasdaq

Forecast to breakeven in 2026

Tenax Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board

Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure

New major risk - Share price stability

The Nasdaq Stock Market LLC Grants Tenax Therapeutics's Request for an Extension Through March 25, 2024 to Evidence Compliance with the $1.00 Per Share Requirement for Continued Inclusion on the Nasdaq Capital Market

Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. Receives a Notice of Allowance from the United States Patent and Trademark Office for its Patent Application

Price target increased by 16% to US$110

Tenax Receives Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Announces the Presentation of Positive Data from a Study of PH-HFpEF Patients Being Treated with Oral Levosimendan

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Tenax Therapeutics, Inc. Receives Formal Notice That the Nasdaq Stock Market LLC

Forecast to breakeven in 2023

Tenax Therapeutics, Inc. Announces Resignation of Executives

Price target decreased to US$4.00

Tenax Therapeutics, Inc. Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

Tenax Therapeutics, Inc. announced that it expects to receive $8 million in funding from Armistice Capital LLC

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Appoints Robyn Hunter to the Board of Directors

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

High number of new and inexperienced directors

Forecast to breakeven in 2022

Price target increased to US$4.75

Independent Director James Mitchum has left the company

Tenax Therapeutics, Inc. Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

High number of new directors

CEO & Director Anthony DiTonno has left the company

Independent Director Chris Rallis has left the company

Independent Director Gregory Pepin has left the company

Independent Chairman Ronald Blanck has left the company

Price target increased to US$4.75

Tenax Therapeutics, Inc. Expands Board of Directors

New 90-day high: US$2.78

Tenax Therapeutics, Inc. (NasdaqCM:TENX) acquired PH Precision Med Inc. for $21.6 million.

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

New 90-day high: US$2.36

New 90-day high: US$1.98

Tenax Therapeutics, Inc. Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020

New 90-day low: US$1.18

Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

New 90-day high: US$1.63

Price target lowered to US$4.23

Tenax Therapeutics, Inc. announced that it has received $4.735325 million in funding

Tenax Therapeutics, Inc. announced that it expects to receive $4.735325 million in funding

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven